
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
Catalent Biologics is a global leader in biopharmaceutical development services, bringing next-generation therapies to the market.
Catalent Biologics is a global leader in biopharmaceutical development services, bringing next-generation therapies to the market. Its recent acquisitions of Paragon Bioservices and MaSTherCell have expanded its service portfolio to include development and manufacturing of cell and gene therapies, alongside new biological entities, biosimilars, sterile injectables, and antibody-drug conjugates.
INTERPHEX Booth # 1147
Catalent Pharma Solutions
14 Schoolhouse Road Somerset, NJ 08873, USA
tel. +1.888.765.8846






